<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03496012</url>
  </required_header>
  <id_info>
    <org_study_id>NSR-REP-01</org_study_id>
    <secondary_id>2015-003958-41</secondary_id>
    <nct_id>NCT03496012</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of AAV2-REP1 for the Treatment of Choroideremia</brief_title>
  <acronym>STAR</acronym>
  <official_title>A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial Of Retinal Gene Therapy For Choroideremia Using An Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NightstaRx Ltd, a Biogen Company</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NightstaRx Ltd, a Biogen Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the efficacy and safety of a single sub-retinal
      injection of AAV2-REP1 in subjects with Choroideremia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3 clinical trial of a gene therapy vector made from adeno-associated virus
      (AAV) called AAV2-REP1 for the treatment of Choroideremia. Participating subjects will be
      required to attend a screening visit during which their suitability for the study will be
      assessed, and eligible subjects will be randomized to either AAV2-REP1 treatment or the
      control group.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 11, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group Study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcomes-assessors will be masked to whether the subject is in the treated or the control group.
Sponsor, subjects and trial centers are masked to dose.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>12 Months</time_frame>
    <description>Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fundus autofluorescence (AF)</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in AF (mm2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography (OCT)</measure>
    <time_frame>12 Months</time_frame>
    <description>Ellipsoid Zone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microperimetry</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in Sensitivity (dB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast Sensitivity</measure>
    <time_frame>12 Months</time_frame>
    <description>Pelli-Robson Chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Color Vision</measure>
    <time_frame>12 Months</time_frame>
    <description>Farnsworth-Munsell 100 Hue Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reading Performance</measure>
    <time_frame>12 Months</time_frame>
    <description>International Reading Speed Texts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self Reported Vision-Targeted Health Status</measure>
    <time_frame>12 Months</time_frame>
    <description>25-item Visual Function Questionnaire (VFQ-25)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">169</enrollment>
  <condition>Choroideremia</condition>
  <arm_group>
    <arm_group_label>AAV2-REP1 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single administration of high-dose AAV2-REP1 in one eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AAV2-REP1 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single administration of low-dose AAV2-REP1 in one eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>AAV2-REP1</intervention_name>
    <description>Sub-retinal injection of AAV2-REP1 after vitrectomy.</description>
    <arm_group_label>AAV2-REP1 High Dose</arm_group_label>
    <arm_group_label>AAV2-REP1 Low Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are willing and able to give informed consent for participation in the study.

          -  Are male and ≥18 years of age.

          -  Have a documented genetically-confirmed diagnosis of CHM.

          -  Have active disease clinically visible within the macular region in the study eye.

          -  Fulfill pre-defined visual acuity criteria.

        Exclusion Criteria:

          -  Have a history of amblyopia in the eligible eye.

          -  Are unwilling to use barrier contraception methods, or abstain from sexual
             intercourse, for a period of 3 months, if treated with AAV2-REP1.

          -  Have had previous intraocular surgery performed in the study eye within 3 months of
             Visit 1.

          -  Have any other significant ocular or non-ocular disease/disorder which, in the opinion
             of the investigator, may either put the subjects at risk because of participation in
             the study, or may influence the results of the study, or the subject's ability to
             participate in the study.

          -  Have participated in another research study involving an investigational product in
             the past 12 weeks or received a gene/cell-based therapy at any time previously.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male subjects only.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Montréal</city>
        <zip>H3A 0E7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z 3N9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Glostrup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 7, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2018</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NightstaRx</keyword>
  <keyword>NSR-REP1</keyword>
  <keyword>Choroideremia</keyword>
  <keyword>CHM</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>AAV</keyword>
  <keyword>REP1</keyword>
  <keyword>Timrepigene Emparvovec</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choroideremia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

